Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Alnylam Pharmaceuticals, Inc. - Common Stock (NQ:ALNY)

234.56 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 208
Open 234.56
Bid (Size) 94.02 (1)
Ask (Size) 371.90 (1)
Prev. Close 234.56
Today's Range 234.56 - 234.56
52wk Range 141.97 - 304.39
Shares Outstanding 118,847,693
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Alnylam to Webcast Conference Call Discussing First Quarter 2025 Financial Results
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 15 Years
Via Benzinga

Performance

YTD
+0.4%
+0.4%
1 Month
-17.2%
-17.2%
3 Month
-11.5%
-11.5%
6 Month
-19.7%
-19.7%
1 Year
+60.9%
+60.9%

More News

Read More
Vertex, Alnylam Best Positioned As Biopharma Braces For Tariff Impact, Goldman Sachs Flags Regeneron, Biogen Risks
Via Benzinga
Topics Government World Trade
Exposures Political Tariff
Is Alnylam Pharmaceuticals Gaining or Losing Market Support?
Via Benzinga
Demystifying Alnylam Pharmaceuticals: Insights From 15 Analyst Reviews
Via Benzinga
$1000 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth This Much Today
Via Benzinga
Alnylam to Webcast Presentation at Needham 24th Annual Virtual Healthcare Conference
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
27 Analysts Assess Alnylam Pharmaceuticals: What You Need To Know
Via Benzinga
If You Invested $100 In This Stock 20 Years Ago, You Would Have This Much Today
Via Benzinga
FDA Approves Sanofi's Hemophilia Drug
Via Benzinga
Exposures Product Safety
Competitive Analysis In The ATTR-CM Field
Via Talk Markets
Topics Stocks / Equities
Alnylam Presents New Data from the HELIOS-B Phase 3 Study of Vutrisiran in Patients with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) at the American College of Cardiology’s Annual Scientific Session 2025
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
FDA Approves Qfitlia™ (fitusiran), the First siRNA (RNAi Therapeutic) for the Treatment of Hemophilia A or B
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Pharmaceuticals Presents 'Convincing Multi-Billion Dollar Opportunity': Analyst Upgrades Stock
Via Benzinga
Exposures Product Safety
Carnival To Rally Around 48%? Here Are 10 Top Analyst Forecasts For Monday
Via Benzinga
Robinhood, Roku And Shopify Are Among Top 10 Large-Cap Gainers Last Week (Mar 17-Mar 21): Are The Others In Your Portfolio?
Via Benzinga
Alnylam Jumps As A New Approval Sets Up Its Next Battle With Pfizer, BridgeBio
Via Investor's Business Daily
Alnylam's Amvuttra Secures FDA Approval For Expanded Use For Rare Heart Disease, Stock Jumps
Via Benzinga
Exposures Product Safety
Alnylam Announces FDA Approval of AMVUTTRA® (vutrisiran), the First RNAi Therapeutic to Reduce Cardiovascular Death, Hospitalizations and Urgent Heart Failure Visits in Adults with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM)
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
How Do Investors Really Feel About Alnylam Pharmaceuticals?
Via Benzinga
Alnylam to Webcast Presentation at Stifel 2025 Virtual CNS Forum
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Announces Retirement of Longtime Board Member, Dr. Phillip A. Sharp, Company Co-Founder and Industry Luminary
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 20 Years
Via Benzinga
Alnylam Highlights Significant Pipeline Progress and Platform Innovation at R&D Day
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Coinbase To Rally Over 11%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga

Frequently Asked Questions

Is Alnylam Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Alnylam Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Alnylam Pharmaceuticals, Inc. - Common Stock trade on?
Alnylam Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Alnylam Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Alnylam Pharmaceuticals, Inc. - Common Stock is ALNY on the Nasdaq Stock Market
What is the current price of Alnylam Pharmaceuticals, Inc. - Common Stock?
The current price of Alnylam Pharmaceuticals, Inc. - Common Stock is 234.56
When was Alnylam Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Alnylam Pharmaceuticals, Inc. - Common Stock was at 04/17/25 04:00 PM ET
What is the market capitalization of Alnylam Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Alnylam Pharmaceuticals, Inc. - Common Stock is 27.88B
How many shares of Alnylam Pharmaceuticals, Inc. - Common Stock are outstanding?
Alnylam Pharmaceuticals, Inc. - Common Stock has 28B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.